Human methylome studies ERP004221 Track Settings
 
Genome-wide methylome profiling of normal breast and breast tumors [Breast Cancer]

Track collection: Human methylome studies

+  All tracks in this collection (455)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       HMR       PMD       CpG methylation ▾       CpG reads ▾      
Select subtracks by views and experiment:
 All views AMR  HMR  PMD  CpG methylation  CpG reads 
experiment
ERX334518 
ERX334519 
ERX334520 
ERX334521 
ERX334522 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 ERX334518  HMR  ERS364139 / ERX334518 (HMR)   Schema 
hide
 ERX334518  AMR  ERS364139 / ERX334518 (AMR)   Schema 
hide
 ERX334518  PMD  ERS364139 / ERX334518 (PMD)   Schema 
hide
 Configure
 ERX334518  CpG methylation  ERS364139 / ERX334518 (CpG methylation)   Schema 
hide
 Configure
 ERX334518  CpG reads  ERS364139 / ERX334518 (CpG reads)   Schema 
hide
 ERX334519  HMR  ERS364140 / ERX334519 (HMR)   Schema 
hide
 ERX334519  AMR  ERS364140 / ERX334519 (AMR)   Schema 
hide
 ERX334519  PMD  ERS364140 / ERX334519 (PMD)   Schema 
hide
 Configure
 ERX334519  CpG methylation  ERS364140 / ERX334519 (CpG methylation)   Schema 
hide
 Configure
 ERX334519  CpG reads  ERS364140 / ERX334519 (CpG reads)   Schema 
hide
 ERX334521  HMR  ERS364142 / ERX334521 (HMR)   Schema 
hide
 ERX334520  AMR  Breast Cancer / ERX334520 (AMR)   Schema 
hide
 ERX334520  PMD  Breast Cancer / ERX334520 (PMD)   Schema 
hide
 Configure
 ERX334520  CpG methylation  Breast Cancer / ERX334520 (CpG methylation)   Schema 
hide
 Configure
 ERX334520  CpG reads  Breast Cancer / ERX334520 (CpG reads)   Schema 
hide
 ERX334522  HMR  ERS364143 / ERX334522 (HMR)   Schema 
hide
 ERX334521  AMR  ERS364142 / ERX334521 (AMR)   Schema 
hide
 ERX334521  PMD  ERS364142 / ERX334521 (PMD)   Schema 
hide
 Configure
 ERX334521  CpG methylation  ERS364142 / ERX334521 (CpG methylation)   Schema 
hide
 Configure
 ERX334521  CpG reads  ERS364142 / ERX334521 (CpG reads)   Schema 
hide
 ERX334522  AMR  ERS364143 / ERX334522 (AMR)   Schema 
hide
 ERX334522  PMD  ERS364143 / ERX334522 (PMD)   Schema 
hide
 Configure
 ERX334522  CpG methylation  ERS364143 / ERX334522 (CpG methylation)   Schema 
hide
 Configure
 ERX334522  CpG reads  ERS364143 / ERX334522 (CpG reads)   Schema 
    

Study title: Genome-wide methylome profiling of normal breast and breast tumors
SRA: ERP004221
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
ERX334518 ERS364139 0.753 15.1 63733 2353.0 1609 998.5 2535 181560.6 0.993 title: Illumina HiSeq 2000 paired end sequencing, Genome-wide methylome profiling of normal breast and breast tumors; ENA-CHECKLIST: ERC000011; ENA-FIRST-PUBLIC: 2015-02-25T17 03 15Z; ENA-LAST-UPDATE: 2018-03-08T16 51 09Z; External Id: SAMEA2234907; INSDC center name: National Yang-Ming University; INSDC first public: 2015-02-25T17 03 15Z; INSDC last update: 2018-03-08T16 51 09Z; INSDC status: public; Submitter Id: E-MTAB-2014 BT198; broker name: ArrayExpress; common name: human; disease: breast cancer; sample_name: E-MTAB-2014 BT198; scientific_name: Homo sapiens; sex: female
ERX334519 ERS364140 0.691 38.7 47418 1049.7 8307 994.8 1040 17079.8 0.994 title: Illumina HiSeq 2000 paired end sequencing, Genome-wide methylome profiling of normal breast and breast tumors; ENA-CHECKLIST: ERC000011; ENA-FIRST-PUBLIC: 2015-02-25T17 03 15Z; ENA-LAST-UPDATE: 2018-03-08T16 50 27Z; External Id: SAMEA2234908; INSDC center name: National Yang-Ming University; INSDC first public: 2015-02-25T17 03 15Z; INSDC last update: 2018-03-08T16 50 27Z; INSDC status: public; Submitter Id: E-MTAB-2014 BT089; broker name: ArrayExpress; common name: human; disease: breast cancer; sample_name: E-MTAB-2014 BT089; scientific_name: Homo sapiens; sex: female
ERX334520 Breast Cancer 0.596 13.2 68650 6593.0 744 906.5 1968 327512.8 0.988 title: Illumina Genome Analyzer IIx paired end sequencing, Genome-wide methylome profiling of normal breast and breast tumors; ENA-CHECKLIST: ERC000011; ENA-FIRST-PUBLIC: 2015-02-25T17 03 15Z; ENA-LAST-UPDATE: 2018-03-08T16 50 27Z; External Id: SAMEA2234909; INSDC center name: National Yang-Ming University; INSDC first public: 2015-02-25T17 03 15Z; INSDC last update: 2018-03-08T16 50 27Z; INSDC status: public; Submitter Id: E-MTAB-2014 MCF7; broker name: ArrayExpress; cell_line: MCF7; cell_type: human breast cancer; common name: human; disease: breast cancer; sample_name: E-MTAB-2014 MCF7; scientific_name: Homo sapiens; sex: female
ERX334521 ERS364142 0.748 31.7 47621 1089.2 6279 973.0 2424 13060.0 0.994 title: Illumina HiSeq 2000 paired end sequencing, Genome-wide methylome profiling of normal breast and breast tumors; ENA-CHECKLIST: ERC000011; ENA-FIRST-PUBLIC: 2015-02-25T17 03 15Z; ENA-LAST-UPDATE: 2018-03-08T16 50 27Z; External Id: SAMEA2234910; INSDC center name: National Yang-Ming University; INSDC first public: 2015-02-25T17 03 15Z; INSDC last update: 2018-03-08T16 50 27Z; INSDC status: public; Submitter Id: E-MTAB-2014 normal breast; broker name: ArrayExpress; common name: human; disease: normal; sample_name: E-MTAB-2014 normal breast; scientific_name: Homo sapiens; sex: female
ERX334522 ERS364143 0.788 25.8 76971 1648.7 2707 1076.3 3586 60910.0 0.995 title: Illumina Genome Analyzer IIx paired end sequencing, Genome-wide methylome profiling of normal breast and breast tumors; ENA-CHECKLIST: ERC000011; ENA-FIRST-PUBLIC: 2015-02-25T17 03 15Z; ENA-LAST-UPDATE: 2018-03-08T16 50 27Z; External Id: SAMEA2234911; INSDC center name: National Yang-Ming University; INSDC first public: 2015-02-25T17 03 15Z; INSDC last update: 2018-03-08T16 50 27Z; INSDC status: public; Submitter Id: E-MTAB-2014 BT126; broker name: ArrayExpress; common name: human; disease: breast cancer; sample_name: E-MTAB-2014 BT126; scientific_name: Homo sapiens; sex: female

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.